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Introduction: Mutations in the tyrosine kinase domain (TKD) of
the epidermal growth factor receptor (EGFR) gene have proven to
be clinically significant in non-small cell lung cancer. However,
relationships between these mutations and EGFR expression or
deletion mutations in the extracellular domain of EGFR (EGFRvIII)
remain unclear. The purpose of this study was to gain further insight
into the clinical significance of these molecular abnormalities in
lung adenocarcinoma.
Methods: We investigated EGFR TKD mutations using direct
sequencing, EGFR protein expression using Western blotting, and
EGFRvIII using reverse transcriptase–polymerase chain reaction in
samples from 48 adenocarcinoma patients. Correlations with various
clinico-pathological features were analyzed.
Results: EGFR TKD mutations were detected in 25 of 48 adeno-
carcinomas (52.1%), and overexpression of EGFR protein was
identified in 19 patients (39.6%). Presence of EGFR TKD mutations
was significantly correlated with EGFR overexpression (p 0.021).
EGFR TKD mutations were significantly correlated with never-
smoker status (p  0.043), absence of emphysematous or fibrotic
appearance on computed tomography (p 0.001), papillary subtype
(p 0.041), and bronchioloalveolar carcinoma features (p 0.045).
EGFRvIII was not detected in any adenocarcinomas. Retrospective
analysis revealed that patients with EGFR TKD mutations displayed
better postoperative prognosis than patients with wild-type EGFR
(p  0.033).
Conclusions: These results suggest that EGFR TKD mutation is
associated with EGFR overexpression, representing an important
factor for consideration when investigating the clinical significance,
including susceptibility to chemotherapy, of EGFR TKD mutations
in adenocarcinoma. EGFRvIII does not seem to play a major role in
the development of lung adenocarcinoma.
Key Words: Lung cancer, Epidermal growth factor receptor, Mu-
tation, EGFRvIII, Overexpression.
(J Thorac Oncol. 2006;1: 787–795)
Non-small cell lung cancer (NSCLC) represents one of themajor causes of death in developed countries.1 NSCLC
patients often relapse after surgery,2 and many patients who
are treated using conventional cytotoxic agents experience
cancer recurrence.3 New therapeutic modalities are thus re-
quired for patients who prove resistant to conventional ap-
proaches.
Epidermal growth factor receptor (EGFR) is a member
of the receptor-type tyrosine kinase (TK) family, and the
molecular status of EGFR in NSCLC has been extensively
analyzed. Initially, overexpression of the EGFR protein or
gene in NSCLC was frequently reported.4 Deletion in exons
2 to 7 of the EGFR gene (EGFRvIII or del2-7EGFR), which
is often found in glioblastoma or glioma,5–7 has also been
identified in a subset of NSCLC patients.8–10 Overexpressed
EGFR is considered to aberrantly activate downstream signal
proteins beyond physiological levels. EGFRvIII also has been
proven to activate these signal proteins and confer prolifera-
tive properties to glioblastoma or glioma cells.5 Thus, it
seems reasonable that EGFR inhibitors might display antitu-
mor activities against cancers harboring EGFR overexpres-
sion or EGFRvIII. In fact, some studies have confirmed
positive correlations between EGFR expression level and
efficiency of gefitinib, a major TK inhibitor (TKI) specific for
EGFR,11 although negative results have also been reported.12
More recently, small mutations in the TK domain
(TKD) of the EGFR gene have frequently been found in
NSCLC, particularly in adenocarcinomas.13,14 Interestingly
these types of mutations are widely recognized as occurring
more frequently in female patients, nonsmokers, tumors with
adenocarcinomatous histology, and Asian populations.15,16
EGFR with such mutations as delE746-A750 in exon 19 and
L858R in exon 21 is considered to be constitutively activated
through phosphorylation, and it displays tumorigenic proper-
ties.13–15,17 Numerous studies have thus reported that
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NSCLCs with TKD mutations in the EGFR gene tend to
show better response to gefitinib than tumors without such
mutations.18,19
These results suggest that clinical features of NSCLC
(and adenocarcinoma in particular), including response to
gefitinib, may be associated with both EGFR mutations and
expression level. Investigation of the correlations between
EGFR mutations and expression level and exploration of
relationships with various clinico-pathological features of
adenocarcinoma is therefore meaningful. However, few stud-
ies have simultaneously investigated EGFR mutations and
expression by Western blotting in adenocarcinoma, and no
studies investigating EGFR TKD mutations have thoroughly
analyzed the presence or absence of EGFRvIII. Furthermore,
previous studies have included only limited information on
patient characteristics such as sex and smoking status.15 The
present study investigated EGFR mutations, both in terms of
EGFR TKD mutations and EGFRvIII, and concurrently ex-
amined expression levels of EGFR in clinical lung adenocar-




A total of 96 Japanese patients with NSCLC underwent
surgery in the Department of Thoracic Surgery at Kyorin
University Hospital between May 2001 and March 2003. Of
these, 48 patients with adenocarcinoma diagnosed by a
trained pathologist were enrolled for further analysis. All
patients underwent pulmonary resection with or without
lymph node dissection. After surgery, some patients under-
went chemotherapy and/or radiotherapy with various regi-
mens. No patient was administered gefitinib before tumor
recurrence. Written informed consent to analyze tissue DNA,
RNA, and protein was obtained from each patient prior to
operation. The authors who conducted molecular analyses
were blinded to the postoperative outcomes of all patients
until all molecular analyses were completed.
Patient Data
Various clinical data were obtained from in- and out-
patient medical records. Clinical and pathological stages of
adenocarcinoma patients were determined in accordance with
the criteria of the tumor-node metastasis classification sys-
tem.20 The following criteria were used to classify smoking
status: never smoker, patients who had smoked fewer than
100 cigarettes in their lifetime; former smoker, patients who
had stopped smoking at least 12 months before diagnosis; and
current smoker. Percentage of forced expiratory volume in 1
second was measured preoperatively in all patients and used
as a parameter for respiratory function. Levels of carcinoem-
bryonic antigen were determined in all patients at the time of
diagnosis as a serological tumor marker. Computed tomog-
raphy (CT) was performed and interpreted by radiologists in
the Department of Radiology at Kyorin University Hospital
who were blinded to EGFR status. Presence of ground-glass
opacity components within the tumor region and emphyse-
matous or fibrotic appearance in adjacent lung tissue was
integrated into the analysis. The World Health Organization
classification system also was used for pathological subclas-
sification of adenocarcinomas regarding papillary subtype
and level of differentiation.21 Status of bronchioloalveolar
carcinoma (BAC) features was determined using a report
from the Memorial Sloan-Kettering Cancer Center.22 Re-
sponses to conventional cytotoxic agents or gefitinib were
assessed using the response evaluation criteria in solid tu-
mors.23
Samples
Lung cancer cell lines NCI-H1650 and H1975 were
purchased from American Type Culture Collection (Manas-
sas, VA) and used as positive controls for mutations.17 Gli-
oblastoma cell line U87MGEGFR with EGFRvIII was
kindly donated by Professor Webster K. Cavenee of the
Ludwig Institute for Cancer Research in San Diego and was
used as a positive control for EGFRvIII mutation.24 Tumor
samples and visually normal lung tissues distant from the
tumor were immediately frozen after resection and preserved
at 80°C. Visually normal lung tissues were confirmed as
containing no tumor component on pathological examination.
Direct Sequencing
Mutations of EGFR in lung cancer tend to cluster
within exons 18 to 21. Direct sequencing analysis of EGFR
from exons 18 to 21 was therefore performed using previ-
ously reported methods25 for all samples, including the two
positive-control NSCLC cell lines.
Reverse Transcriptase–Polymerase Chain
Reaction
EGFRvIII is generated by total (801 bp) deletion of
exons 2 to 7 in the extracellular domain of the EGFR gene.
Because reverse transcriptase–polymerase chain reaction
(RT-PCR) is reportedly useful in detecting this deletion in
glioblastoma,5 it was employed in this study. For detection of
the 801-bp deletion, tumor cDNA and primers (Table 1) were
subjected to 40 cycles of polymerase chain-reaction amplifi-
cation.
Western Blotting
For EGFR Western blotting analysis, 100 g of tumor
or normal-lung protein was used. Samples were subjected to
Western blotting analyses using anti-EGFR monoclonal an-
tibody (BD Biosciences, San Jose, CA) according to the
instructions of the manufacturer. This antibody binds to the
intracellular domain of EGFR protein (amino acids 1020–
1046) distant from TKD. Equal loading of extract was con-
firmed by Western blotting using anti--actin antibody
(Sigma, St. Louis, MO). Normal-lung protein usually dem-
onstrated either a very weak EGFR band (180 kDa) or no
band on Western blotting. The EGFR expression level for
each tumor was determined in comparison with expression in
corresponding normal-lung protein as follows: (), very
weak or no band similar to normal lung; (), easily visible
band; and (2), very strong band similar to levels of cell
lines. An EGFR expression level of () or (2) was defined
as indicating EGFR overexpression.
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Statistical Analysis
The significance of differences in categorical data was
tested using the 2 test or Fisher’s exact test. Logistic regression
analysis was performed to determine independent corresponding
factors. Differences in overall survival and time to progression
(TTP) after surgery according to presence or absence of EGFR
gene mutations or EGFR protein overexpression were compared
using Kaplan-Meier curves and log-rank tests. SPSS for Win-
dows version 11.0 software (SPSS, Chicago, IL) was used to
perform all statistical calculations. All statistical tests were two
sided, and differences were considered statistically significant
for values of p  0.05.
RESULTS
Patient Characteristics
Patients comprised 21 women (43.8%) and 27 men
(56.3%). Median age for the 48 patients was 68.5 years
(range, 42–83 years). Subjects comprised 24 never smokers
(50.0%), 17 former smokers (35.4%), and seven current
smokers (14.6%). Clinical stages of patients were as follows:
stage IA (T1 N0 M0) in 22 patients (45.8%); stage IB (T2 N0
M0) in 16 patients (33.3%); stage IIA (T1 N1 M0) in one
patient (2.1%); stage IIB (T2 N1 M0 or T3 N0 M0) in two
patients (4.2%); stage IIIA (T1–3 N2 M0 or T3 N1–2 M0) in
six patients (12.5%); and stage IIIB (T4 any N M0 or any T
N3 M0) in one patient (2.1%). Pathological stages were as
follows: stage IA in 14 patients (29.2%); stage IB in 11
patients (22.9%); stage IIA in three patients (6.25%); stage
IIB in four patients (8.3%); stage IIIA in six patients (12.5%);
stage IIIB in seven patients (14.6%); and stage IV (any T any
N M1) in three patients (6.25%). Details of other character-
istics are shown in Tables 2 and 3.
Mutations and Expression of EGFR in Cell Lines
Direct sequencing analysis was performed for NCI-
H1650 and H1975, confirming that both cell lines possess the
expected mutations (H1650: deletion of nt.2481-2495;
H1975: L858R and T790M). Western blotting demonstrated
very strong EGFR expression levels in both cell lines, sug-
gesting overexpression of EGFR. H1975 displayed another
band of approximately 50 kDa (Figure 1A).
EGFR TKD Mutations in Patient Samples
EGFR mutations in TKD are summarized in Table 2.
At least one of of the mutations within exons 18 to 21 was
found in 25 of the 48 adenocarcinomas (52.1%).
Deletions in exon 19 were found in 11 of 48 adenocar-
cinoma samples (22.9%). Types of deletion varied, but eight
of the 11 mutations were delE746-A750 (i.e., either Del1 [del
nt.2481-2495] or Del2 [del nt.2482-2496]). Each of the re-
maining three patients displayed a different type of mutation:
Del3 (delL747-T751), Del4 (delE746-R748), and Del5
(delL747-P753insS).
Mutations within exon 21 were found in 13 of 48
adenocarcinomas (27.1%), and all were identical to the
L858R mutation. Two adenocarcinoma patients with L858R
displayed a second mutation, one with E709G in exon 18, and
the other with H870R in exon 21.
Mutation within exon 18 was found in only one patient
(2.1%). This mutation was the previously reported E709G,
and the patient also displayed L858R. Another patient exhib-
ited a 1-bp insertion at intron 17, but sequencing analysis of
cDNA revealed that cDNA of the sample from this patient
was wild type, indicating that the insertion did not affect
mRNA formation. This mutation was considered a silent
mutation and was not included for further analysis.
Mutation within exon 20 was found in only one patient
(2.1%). This patient displayed an N771SinsH mutation in exon
20 that had not previously been reported in NSCLC (Figure 2A).
EGFRvIII in Patient Samples
We performed RT-PCR of the EGFR extracellular
domain in 48 adenocarcinoma samples, but none showed a
short 352-bp band. These results indicate that no adenocar-
cinoma samples in this study contained EGFRvIII mutations
(Table 2, Figure 2B).
EGFR Protein Expression in Patient Samples
Expression levels of EGFR protein were categorized
into three groups using Western blotting analysis: (2), (),
and (). Because all normal-lung samples showed () (weak
or negative) EGFR expression in our study, tumor samples
with (2) or () expression were considered representative
of EGFR overexpression. Expression levels of -actin were
(2) in all tumor and normal-lung samples, suggesting that
the protein samples were suitable for analysis (Figure 1B).
EGFR overexpression was present in 19 of the 48 patients
TABLE 1. EGFR Primers
Nucleotide
PCR primers
Exon 18 sense 5=-CAAGTGCCGTGTCCTGGCACCCAAGC-3=
Exon 18 antisense 5=-CCAAACACTCAGTGAAACAACAAA
GAG-3=
Exon 19 sense 5=-TGCATCGCTGGTAACAT-3=
Exon 19 antisense 5=-AGCTGCCAGACATGAGAA-3=
Exon 20 sense 5=-ATTCATGCGTCTTCACCTGG-3=
Exon 20 antisense 5=-TGAGAGTTTCCACATGCAGAT-3=
Exon 21 sense 5=-TGGTCAGCAGCGGGTTACATCTTC-3=
Exon 21 antisense 5=-CAATACAGCTAGTGGGAAGGCAGC-3=
Sequencing reaction
primers
Exon 18 sense 5=-CTTTCCAGCATGGTGA-3=
Exon 18 antisense 5=-GATGGAAATATACAGC-3=
Exon 19 sense 5=-ACCATCTCACAATTGCCAG-3=
Exon 19 antisense 5=-TGAGGTTCAGAGCCAT-3=
Exon 20 sense 5=-AGGAAGCCTACGTGAT-3=
Exon 20 antisense 5=-TGAGAGTTTCCACATGCAGAT-3=
Exon 21 sense 5=-CTTTGGATCAGTAGTC-3=
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1 80 F N IB Pap AD Mod Del2 (exon 19)  Yes
2 42 M F14 IIIB Pap AD Well Del1 (exon 19) 2
3 63 M C41 IIA Others AWBF Mod Del2 (exon 19)  Yes
4 56 M F5 IV Others AD Well Del1 (exon 19) 2 Yes PR
5 57 F N IB Pap AWBF Well Del1 (exon 19) 
6 66 F N IA Others AWBF Well Del3 (exon 19) 
7 60 M F44 IB Pap AD Well Del4 (exon 19) 
8 68 F N IIA Pap AWBF Mod Del2 (exon 19) 
9 76 M N IA Pap AWBF Well Del5 (exon19) 
10 54 F N IIIA Pap AWBF Well Del1 (exon 19) 
11 70 M F13 IV Others AD Poor Del1 (exon 19) 2
12 79 F N IA Pap AWBF Well N771S insH (exon 20) 
13 70 F N IB Others AWBF Well L858R (exon 21) and 2
H870R (exon 21)
14 64 F N IA Pap AWBF Mod L858R (exon 21) 
15 70 F N IA Pap AD Mod L858R (exon 21) 
16 54 F N IIIB Pap AWBF Poor L858R (exon 21)  Yes SD
17 62 F N IIIA Pap AWBF Mod L858R (exon 21)  Yes
18 56 M N IIIB Pap AWBF Well L858R (exon 21)  Yes SD
19 65 F N IIIA Pap AWBF Mod L858R (exon 21)  Yes
20 70 F F30 IIA Pap AD Well L858R (exon 21) 
21 77 M C29 IIIB Pap AWBF Well L858R (exon 21)  Yes
22 81 M N IV Pap AWBF Mod L858R (exon 21)  Yes
23 76 M F56 IA Pap AWBF Well L858R (exon 21) 
24 60 F N IA Pap AWBF Well L858R (exon 21) and  Yes
E709G (exon18)
25 69 M F25 IA Pap AWBF Mod L858R (exon 21)  Yes
26 73 F N IIIB Pap AD Mod WT (Intron 17 ins)  Yes PD
27 69 M C26 IA Others AD Well WT 
28 66 M F80 IB Others AWBF Well WT  Yes
29 59 M F35 IIB Others AD Poor WT 2 Yes
30 73 M F75 IIIA Pap AWBF Well WT  Yes SD
31 81 M F88 IA Pap AWBF Well WT  Yes PD
32 61 F F22 IB Others AD Poor WT 
33 70 M F10 IB Pap AWBF Well WT 
34 56 F N IIIB Others AWBF Well WT 
35 78 M F200 IIB Pap AD Mod WT 
36 81 M N IB Others AWBF Poor WT  Yes
37 74 M F60 IA Others AWBF Poor WT  Yes
38 52 F N IA Pap AWBF Well WT 
39 69 M N IIB Others AD Well WT  Yes PD
40 50 F N IIIA Others AD Poor WT  Yes PD
41 68 M C30 IA Pap AD Mod WT 
42 54 M F20 IA Others AD Mod WT  Yes
43 75 M F60 IB Others AD Poor WT 
44 83 F N IB Pap AWBF Well WT  Yes
45 75 F N IIIB Pap AWBF Mod WT  Yes PD
46 56 M C64 IIIA Pap AD Mod WT  Yes
47 50 M C60 IB Pap AD Mod WT 
48 73 M C55 IIIB Pap AD Mod WT  Yes
M, male; F, female; C, current smoker; F, former smoker; N, never smoker; Pap, papillary; BAC, bronchioloalveolar carcinoma; AD, adenocarcinoma without BAC features;
AWBF, adenocarcinoma with BAC features; well, well differentiated; mod, moderately differentiated; poor, poorly differentiated; del, deletion mutation; WT, wild type; ins, insertion
mutation; Del1, del nt.2481-2495; Del2, del nt.2482-2496; Del3, delL747-T751; Del4, delE746-R748; Del5, delL747-P753insS; PR, partial response; SD, stable disease; PD,
progressive disease; NE, not evaluated. Numbers in Smoking column indicate pack-years. “Others” in Histologic subtype column indicates acinar, solid, or BAC.
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(39.5%), with five patients (10.4%) showing (2) expression.
Of the 19 samples with EGFR overexpression, 14 (73.7%)
showed EGFR TKD mutations (Table 2). In contrast, 11 of 29
(37.9%) samples without overexpression displayed EGFR
TKD mutations.
Correlation of EGFR TKD Mutations with
Clinico-Pathological and Molecular Features
Correlations between EGFR TKD mutations and vari-
ous clinical, pathological, and molecular features were inves-
tigated in patients with adenocarcinoma (Table 3). Using
univariate analysis, never-smoker status (p  0.043), papil-
lary subtype (p  0.041), presence of BAC features (p 
0.045), absence of emphysematous or fibrotic appearances on
CT (p  0.001), and EGFR overexpression (p  0.015) were
found to be significantly correlated with EGFR TKD muta-
tions. Under multivariate analysis, EGFR overexpression was
the only factor identified as significant (p  0.021).
Gefitinib Response of Patients
A total of nine patients with or without prior chemo-
therapy were treated using gefitinib after relapse. Response
TABLE 3. Relationship Between EGFR TKD Mutations and Clinico-pathological/Molecular Features of Adenocarcinoma
Patients
Total Mutation (%) Wild (%) p value
n 48 25 52.1 23 47.9
Sex
Women 21 14 66.7 7 33.3
Men 27 11 40.7 16 59.3 0.074
Age (yr)
65 19 11 57.9 8 42.1
65 29 14 48.3 15 51.7 0.514
Smoking status
Never 24 16 66.7 8 33.3
Current/former 24 9 37.5 15 62.5 0.043a
GGO component
Present 11 6 54.5 5 45.5
Absent 37 19 51.4 18 48.6 0.382
Emphysematous and/or fibrotic appearance on CT
Present 8 0 0.0 8 100.0
Absent 40 25 62.5 15 37.5 0.001a
FEV1.0%
70 36 20 55.6 16 44.4
70 12 5 41.7 7 58.3 0.404
CEA (ng/ml)
5 26 16 61.5 10 38.5
5 22 9 40.9 13 59.1 0.154
Differentiation
Well/mod 40 23 57.5 17 42.5
Poor 8 2 25.0 6 75.0 0.093
Papillary subtype
Yes 32 20 62.5 12 37.5
No 16 5 31.3 11 68.8 0.041a
BAC features
Present 28 18 64.3 10 35.7
Absent 20 7 35.0 13 65.0 0.045a
EGFR expression
(2)/() 19 14 73.7 5 26.3
() 29 11 37.9 18 62.1 0.015a
Pathological stage
I/II 32 16 50.0 16 50.0
III/IV 16 9 56.3 7 43.8 0.683
Postoperative recurrence
Yes 25 11 44.0 14 56.0
No 23 14 60.9 9 39.1 0.243
GGO, ground-glass opacity; CT, computed tomography; FEV1.0% forced expiratory volume in 1 second (%); CEA, carcinoembryonic antigen; BAC, bronchioloalveolar
carcinoma. a Statistically significant (p  0.05).
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rate was 33.3% (one in three) for patients with EGFR TKD
mutations and 0% (out of six) for patients with wild-type
EGFR. The sole patient who responded to gefitinib therapy
showed both EGFR TKD mutation and EGFR (2) expres-
sion (Table 2).
Survival and TTP in Adenocarcinoma Patients
Figure 3A shows overall survival after surgery in ade-
nocarcinoma patients with or without EGFR TKD mutations,
according to Kaplan-Meier analysis. The median period of
observation was 31.9 months (range, 1.32–48.1 months).
Log-rank testing revealed a significant difference in overall
survival between patients with mutation-type EGFR and
those with wild-type EGFR (p  0.033). We then analyzed
whether the presence or absence of EGFR TKD mutation has
any influence on the overall survival of patients receiving
gefitinib therapy. Among patients treated with gefitinib, those
with mutation showed a significantly better overall survival
rate than those without mutation. Among patients without
gefitinib therapy, however, no differences in overall survival
rate were seen between patients with or without mutation
(Figure 3B).
Figure 3C shows TTP after surgery for adenocarcinoma
patients with or without EGFR TKD mutations. Differences
in TTP between these two populations were not significant
(p  0.105).
Correlations between EGFR expression levels and
overall survival were also analyzed (Figure 3D), but no
significant difference was identified (p  0.385).
DISCUSSION
This study analyzed correlations between EGFR TKD
gene mutations in clinical lung adenocarcinoma samples and
various clinical, pathological, and molecular features. Most
strikingly, the present study offers the first demonstration of
correlations between EGFR TKD mutations and EGFR over-
expression by Western blotting in adenocarcinoma patients.
EGFR expression levels were analyzed in all adenocarcinoma
samples using Western blotting analysis, revealing that
EGFR TKD mutations were strongly correlated with EGFR
overexpression by Western blotting. EGFR TKD mutations
were present in 14 of 19 samples with EGFR overexpression
(73.7%). This correlation resembles overexpression of the
EGFR gene in EGFRvIII in glioblastoma or glioma, where
tumors with EGFRvIII are frequently associated with EGFR
overexpression through gene amplification. Deletion of the
extracellular domain is considered to result from instability
caused by gene amplification.5–7 Along a similar line, tumors
with overexpression of the EGFR gene may be generated by
amplification in lung adenocarcinoma, and EGFR TKD mu-
tations may be caused by instability in the amplified gene.26
Previously, most studies analyzing EGFR overexpres-
sion in lung cancer have used immunohistochemistry (IHC).
This method offers the advantage that, under ideal conditions,
distributions and proportions of EGFR-positive cells in the
tumor can be examined at the cellular level. However, the
quality of staining depends largely on the condition of sam-
ples and the techniques used, and accurately assessing the
proportion of positive cells in tumor is often difficult. In
addition, cutoff levels of overexpression can vary consider-
ably among reports, and the rate of EGFR overexpression
actually ranges from 20 to 80% in reported cases.4 These
results suggest that IHC is not a very accurate or objective
method for evaluating EGFR overexpression. Western blot-
ting, used here for the analysis of EGFR overexpression,
allows easy comparison of protein expression levels between
tumor and normal-lung samples and is thus assumed to be at
least as reliable as IHC.
We also investigated EGFRvIII in all samples using
RT-PCR, and we found that this mutation was very rare in
NSCLC, particularly in adenocarcinomas. Contrary to our
findings, two previous studies have reported the presence of
EGFRvIII in 16 and 39% of NSCLCs, including adenocarci-
FIGURE 1. EGFR protein expression analysis by Western
blotting. EGFR protein expression was classified into three
levels: (2), (), and (). (A) NCI-H1650 and H1975 cell
lines. Both cell lines show strong EGFR expression. (B) Clini-
cal samples with (2) (case 4), () (case 26), and () (case
16) expression level. EGFR expression of corresponding nor-
mal-lung tissue and -actin expression of tumor and normal-
lung tissue are also shown.
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nomas.8–10 The reason for this discrepancy is unclear, but
differences in methods of detecting EGFRvIII may have
contributed. RT-PCR as used in our study has been proven to
be capable of detecting EGFRvIII as efficiently as IHC in
glioblastoma.5 In contrast, the specificity of the antibody used
to detect EGFRvIII by IHC might have contributed to over-
estimation of EGFRvIII-positive lung cancers in previous
studies. Another possible explanation is that EGFRvIII could
be generated not through the generation of mRNA with
deletion of exons 2 to 7, but by alternative mechanisms. Most
recently, consistent with our results, a study with a larger
number of patients reported that EGFRvIII was found only in
squamous cell carcinomas, not in adenocarcinomas.27
The present study also clarified the correlation of EGFR
TKD mutations with various clinico-pathological features.
Nonsmoker status, papillary subtype, and presence of BAC
features were correlated with a high rate of EGFR TKD
mutations, as already reported in previous studies.15,19
Among the clinico-pathological factors analyzed, we discov-
ered that an absence of emphysematous or fibrotic appearance
on CT was significantly correlated with EGFR TKD muta-
tions (p 0.001). In fact, no mutations were found in patients
with these findings on CT. This result is interesting because
emphysematous or fibrotic appearance on CT is probably a
consequence of smoking. Patients with lung cancer often do
not objectively declare smoking history, and smoking status
by patient declaration does not always reflect the patient’s
true history of smoking. Emphysematous or fibrotic appear-
ance on CT may have reflected smoking habit more accu-
rately than self-declaration and, accordingly, correlated with
absence of EGFR TKD mutations. The emphysematous and
fibrotic lung itself may also display an association with the
development of lung cancer via mechanisms other than
EGFR TKD mutations.
Although several features have been proven to be
associated with EGFR TKD mutations, multivariate analysis
revealed EGFR overexpression as the sole independent factor
correlated with EGFR TKD mutations. This result may indi-
cate that EGFR overexpression should be analyzed simulta-
neously in clinical samples to clarify the clinical significance
of EGFR TKD mutations.
Prognosis for adenocarcinoma patients after surgery,
including gefitinib-treated patients, was also analyzed in
relation to EGFR TKD mutations. In the present study,
overall survival was significantly better in patients with
EGFR TKD mutations than in patients without such muta-
tions.16,28 One possible explanation for this finding is that
lung adenocarcinomas with EGFR TKD mutations are intrin-
sically more benign than those without these mutations.
Alternately, tumors with EGFR TKD mutations may be more
susceptible to specific therapies, including gefitinib, resulting
in better prognosis than tumors without mutations. Although
FIGURE 2. EGFR mutations. (A)
N771SinsH in exon 20 (antisense direc-
tion); (B) results of RT-PCR for detecting
EGFRvIII. U87MGEGFR glioblastoma cell
line showed a short 352-bp band, indicat-
ing that EGFRvIII was included. No adeno-
carcinoma samples showed a short 352-bp
band (cases 19, 44, and 48), but one
large-cell carcinoma sample (case 58)
showed a weak 352-bp band (not in-
cluded in the current study).
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the number of patients was small, we have shown in this
retrospective study that gefitinib therapy is specifically effec-
tive for patients with EGFR TKD mutation (Figure 3B).
These results may suggest that the latter possibility is more
likely. However, further studies based on appropriate study
designs, such as randomized control studies, are essential to
evaluate the influence of EGFR TKD mutations on patient
prognosis.
Many previous studies have reported close correlations
between susceptibility to gefitinib and various EGFR abnor-
malities. It has not yet been elucidated whether EGFR abnor-
malities such as gene amplification, mutation, or EGFR
protein overexpression represent the main contributions to
response to TKIs. Cappuzzo et al.29 recently analyzed the
effects of EGFR gene amplification and TKD mutation on
response to gefitinib and showed a stronger correlation for
amplification than for TKD mutation. EGFR gene copy
number (i.e., gene amplification) is also reportedly correlated
with EGFR protein overexpression.30 These results suggest
that EGFR protein overexpression is more strongly correlated
with response to TKIs than mutation. However, in the present
study, using Western blot, EGFR protein overexpression was
not directly correlated to gefitinib response (data not shown).
This may be attributable to the limited number of patients
treated with gefitinib and the retrospective nature of the
present study. EGFR protein expression level was analyzed
rather than gene amplification in this study because protein
expression levels are considered to more directly reflect the
amount of EGFR protein to be inhibited by TKIs. We are
currently investigating correlations between EGFR gene am-
plification in DNA level and mRNA expression level, and the
results of this pending investigation are expected to provide
some insight into this issue. The molecular mechanisms
underlying gefitinib susceptibility in terms of EGFR expres-
sion level and the presence of EGFR TKD mutations remain
to be determined in future studies.
In conclusion, we have confirmed that EGFR overex-
pression is closely related to EGFR TKD mutations. Analysis
FIGURE 3. Kaplan-Meier analysis of adenocarcinoma patients. (A) Overall survival rate after surgery in patients with or with-
out EGFR TKD mutations. Log-rank testing revealed that the overall survival rate was significantly better for patients with EGFR
TKD mutations than for those without mutations (p  0.033). (B) The overall rate of survival after surgery was analyzed for
gefitinib therapy and EGFR mutations. For gefitinib-treated patients, differences between patients with and without EGFR mu-
tations were significant (p  0.016). For patients without gefitinib therapy, however, no significant differences were noted
between patients with and without EGFR mutations (p  0.445). (C) TTP after surgery for patients with or without EGFR TKD
mutations. Differences in TTP between the two populations were not significant (p  0.105). (D) Overall survival after surgery
for patients with or without EGFR overexpression. Differences were not significant (p  0.385).
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of EGFR mutations together with EGFR protein expression
level in clinical studies will facilitate an understanding of the
role of EGFR in lung cancer and lead to the development of
new anticancer agents.
ACKNOWLEDGMENTS
We wish to thank Professor Webster K. Cavenee of the
Ludwig Institute for Cancer Research at San Diego for the
kind gift of glioblastoma cell line U87MGEGFR and Motoo
Nagane, MD, PhD from the Department of Neurosurgery at
Kyorin University Hospital for his technical advice.
REFERENCES
1. Jemal A, Tiwari RC, Murray T, et al. American Cancer Society. Cancer
statistics, 2004. CA Cancer J Clin 2004;54:8–29.
2. Goya T, Asamura H, Yoshimura H, et al. Prognosis of 6644 resected
non-small cell lung cancers in Japan: a Japanese lung cancer registry
study. Lung Cancer 2006;50:227–234.
3. Schiller JH, Harrington D, Belani CP, et al. Eastern Cooperative On-
cology Group. Comparison of four chemotherapy regimens for advanced
non-small-cell lung cancer. N Engl J Med 2002;346:92–98.
4. Nakamura H, Kawasaki N, Taguchi M, et al. Survival impact of
epidermal growth factor receptor overexpression in patients with non-
small-cell lung cancer: a meta-analysis. Thorax 2006;61:140–145.
5. Worm K, Dabbagh P, Schwechheimer K. Reverse transcriptase poly-
merase chain reaction as a reliable method to detect epidermal growth
factor receptor exon 2-7 gene deletion in human glioblastomas. Hum
Pathol 1999;30:222–226.
6. Ekstrand AJ, Sugawa N, James CD, et al. Amplified and rearranged
epidermal growth factor receptor genes in human glioblastomas reveal
deletions of sequences encoding portions of the N- and /or C-terminal
tails. Proc Natl Acad Sci U S A 1992;89:4309–4313.
7. Wong AJ, Ruppert JM, Bigner SH, et al. Structual alterations of the
epidermal growth factor receptor gene in human gliomas. Proc Natl
Acad Sci U S A 1992;89:2965–2969.
8. Garcia de Palazzo IE, Adams GP, Sundareshan P, et al. Expression of
mutated epidermal growth factor receptor by non-small cell lung carci-
nomas. Cancer Res 1993;53:3217–3220.
9. Okamoto I, Kenyon LC, Emlet DR, et al. Expression of constitutively
activated EGFRvIII in non-small cell lung cancer. Cancer Sci 2003;94:
50–56.
10. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer
therapy. N Engl J Med 2006;353:172–187.
11. Santoro A, Cavina R, Latteri F, et al. Activity of a specific inhibitor,
gefitinib (IresaTM, ZD1839), of epidermal growth factor receptor in
refractory non-small-cell lung cancer. Ann Oncol 2004;15:33–37.
12. Kim KS, Jeong JY, Kim YC, et al. Predictors of the response to gefitinib
in refractory non-small cell lung cancer. Clin Cancer Res 2006;11:2244–
2251.
13. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the
epidermal growth factor receptor underlying responsiveness of non-
small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129–2139.
14. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer:
correlation with clinical response to gefitinib therapy. Science 2004;304:
1497–1500.
15. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are
common in lung cancers from “never smokers” and are associated with
sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A
2004;101:13306–13311.
16. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features
associated with epidermal growth factor receptor gene mutations in lung
cancers. J Natl Cancer Inst 2006;97:339–346.
17. Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR
mutations in lung cancer activate anti-apoptotic pathways. Science
2004;305:1163–1167.
18. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal
growth factor receptor gene predict prolonged survival after gefitinib
treatment in patients with non-small-cell lung cancer with postoperative
recurrence. J Clin Oncol 2006;23:2513–2520.
19. Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor
gene mutations and increased copy numbers predict gefitinib sensitivity
in patients with recurrent non-small-cell lung cancer. J Clin Oncol
2006;23:6829–6837.
20. International Union Against Cancer. Lung Tumors. In Sobin LH, Wit-
tekind CH (Eds.), TNM Classification of Malignant Tumours, 5th ed.
New York, NY: Wiley-Liss, 1997, pp 91–97.
21. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Histor-
ical Typing of Lung and Pleural Tumors, World Health Organization
International Histological Classification of Tumors. Berlin: Springer,
1999.
22. Ebright MI, Zakowski MF, Martin J, et al. Clinical pattern and patho-
logic stage but not histologic features predict outcome for bronchioloal-
veolar carcinoma. Ann Thorac Surg 2002;74:1640–1647.
23. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to
evaluate the response to treatment in solid tumors. European Organiza-
tion for Research and Treatment of Cancer, National Cancer Institute of
the United States, National Cancer Institute of Canada. J Natl Cancer
Inst 2000;92:205–216.
24. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of
the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med
2006;353:2012–2024.
25. Ohnishi H, Ohtsuka K, Ooide A, et al. A simple and sensitive method for
detecting major mutations within the tyrosine kinase domain of the
epidermal growth factor receptor gene in non-small-cell lung carcinoma.
Diagn Mol Pathol 2006;15:101–108.
26. Amann J, Kalyankrishna S, Massion PP, et al. Aberrant epidermal
growth factor receptor signaling and enhanced sensitivity to EGFR
inhibitors in lung cancer. Cancer Res 2006;65:226–235.
27. Ji H, Zhao X, Yuza Y, et al. Epidermal growth factor receptor variant III
mutations in lung tumorigenesis and sensitivity to tyrosine kinase
inhibitors. Proc Natl Acad Sci U S A 2006;103:7817–7822.
28. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth
factor receptor gene in lung cancer: biological and clinical implications.
Cancer Res 2004;64:8919–8923.
29. Cappuzzo F, Hirsh FR, Rossi E, et al. Epidermal growth factor receptor
gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
J Natl Cancer Inst 2006;97:643–655.
30. Hirsh FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor
receptor in non-small-cell lung carcinomas: correlation between gene
copy number and protein expression and impact on prognosis. J Clin
Oncol 2003;21:3798–3807.
Journal of Thoracic Oncology • Volume 1, Number 8, October 2006 TKD Mutations of the EGFR Gene
Copyright © 2006 by the International Association for the Study of Lung Cancer 795
